These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34268986)

  • 1. Patient perspective on sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy in HER2-negative breast cancer patients.
    Altundag K
    J BUON; 2021; 26(3):1169. PubMed ID: 34268986
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials.
    Bria E; Carbognin L; Furlanetto J; Pilotto S; Bonomi M; Guarneri V; Vicentini C; Brunelli M; Nortilli R; Pellini F; Sperduti I; Giannarelli D; Pollini GP; Conte P; Tortora G
    Cancer Treat Rev; 2014 Aug; 40(7):847-56. PubMed ID: 24877987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients.
    Tesch ME; Chia SK; Simmons CE; LeVasseur N
    Breast Cancer Res Treat; 2021 May; 187(1):167-176. PubMed ID: 33611678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nine-lncRNA signature predicts distant relapse-free survival of HER2-negative breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy.
    Sun M; Liu X; Xia L; Chen Y; Kuang L; Gu X; Li T
    Biochem Pharmacol; 2021 Jul; 189():114285. PubMed ID: 33069665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?
    Bozovic-Spasojevic I; Azim HA; Paesmans M; Suter T; Piccart MJ; de Azambuja E
    Lancet Oncol; 2011 Mar; 12(3):209-11. PubMed ID: 21354372
    [No Abstract]   [Full Text] [Related]  

  • 6. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
    Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
    Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer.
    Wu J; Li S; Jia W; Su F
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1505-10. PubMed ID: 21830158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.
    Natoli C; Vici P; Sperduti I; Grassadonia A; Bisagni G; Tinari N; Michelotti A; Zampa G; Gori S; Moscetti L; De Tursi M; Panebianco M; Mauri M; Ferrarini I; Pizzuti L; Ficorella C; Samaritani R; Mentuccia L; Iacobelli S; Gamucci T
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1229-40. PubMed ID: 23604446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the sequence of taxane administration affect the outcome of patients with breast cancer in the adjuvant and neoadjuvant settings?
    Alkan A; Sahin U; Altundag K
    Med Oncol; 2010 Dec; 27(4):1430. PubMed ID: 19876779
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
    Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
    Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
    Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
    J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of anthracyclines in the treatment of early breast cancer.
    Gianni L; Norton L; Wolmark N; Suter TM; Bonadonna G; Hortobagyi GN
    J Clin Oncol; 2009 Oct; 27(28):4798-808. PubMed ID: 19687331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxanes and anthracyclines in early breast cancer: which first?
    Wildiers H; Forceville K; Paridaens R; Joensuu H
    Lancet Oncol; 2010 Mar; 11(3):219-20. PubMed ID: 20202604
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    Harbeck N; Gluz O
    Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
    Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential anthracycline and weekly paclitaxel might be more effective compared to docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients.
    Altundag K
    J BUON; 2021; 26(3):1172. PubMed ID: 34268990
    [No Abstract]   [Full Text] [Related]  

  • 17. [Response and prognosis of neoadjuvant dose-dense or standard schedule chemotherapy with anthracyclines and taxanes for Luminal B breast cancer].
    Qiu AF; Miao ZL; Ge GK; Wang CB; Bian J; Ma HY; Xu Q
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(44):3466-3470. PubMed ID: 29275580
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.
    Manso L; Moreno Antón F; Izarzugaza Perón Y; Delgado Mingorance JI; Borrega García P; Echarri González MJ; Martínez-Jañez N; López-González A; Olier Garate C; Ballesteros García A; Chacón López-Muñíz I; Ciruelos Gil E; García-Sáenz JA; Paz-Ares L
    Breast J; 2019 Mar; 25(2):219-225. PubMed ID: 30734437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma.
    Zhou B; Yang DQ; Xie F
    Chin Med J (Engl); 2008 Mar; 121(5):387-91. PubMed ID: 18364105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival.
    Ladoire S; Arnould L; Mignot G; Apetoh L; Rébé C; Martin F; Fumoleau P; Coudert B; Ghiringhelli F
    Br J Cancer; 2011 Jul; 105(3):366-71. PubMed ID: 21750556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.